Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Staar Surgical to $45 from $50 and keeps a Neutral rating on the shares following hte investor day event. Staar Surgical’s long-range plan includes a solid topline outlook and improving profitability despite near-term investments, the analyst tells investors in a research note. The LRP was as expected and Staar’s topline growth expectations are reasonable, but Piper believes near-term headwinds remain and looks to get more comfortable with the topline numbers.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on STAA:
- Staar Surgical downgraded to Hold from Buy at Benchmark
- Staar Surgical sees FY26 sales $500M-$550M, operating margin of 12%-16%
- Staar Surgical to replace Urstadt Biddle in S&P 600 at open on 8/22
- Dolby to replace Staar Surgical in S&P 400 at open on 8/22
- Staar Surgical price target lowered to $45 from $50 at Stifel